{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:12:32Z","timestamp":1791947552888,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-RS-2023-00207857"],"award-info":[{"award-number":["NRF-RS-2023-00207857"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-RS-2025-00515840"],"award-info":[{"award-number":["NRF-RS-2025-00515840"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00440682"],"award-info":[{"award-number":["RS-2024-00440682"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C1654"],"award-info":[{"award-number":["HI22C1654"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI22C1654"],"award-info":[{"award-number":["HI22C1654"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite therapeutic advances, ovarian cancer remains a major clinical challenge owing to its frequent metastasis and chemoresistance, which are often driven by cancer stem cells (CSCs) and proangiogenic signaling. Here we demonstrated that dihydroartemisinin (DHA), a derivative of the antimalarial drug artemisinin, inhibits CSC characteristics, tumor neovascularization and resistance to carboplatin via a microRNA-dependent mechanism in ovarian cancer. DHA substantially inhibited CSC properties, tumorigenicity and vascular endothelial growth factor A (VEGF-A)-mediated tumor neovascularization in ovarian cancer. Moreover, the combined treatment with DHA and carboplatin produced a synergistic effect that reduced tumor burden, chemoresistance and peritoneal dissemination in vivo. Mechanistically, DHA downregulated BMI-1 and VEGF-A\/vascular endothelial growth factor receptor 2 (VEGFR2), which are critical factors in CSC maintenance and metastasis, via the upregulation of miR-200b. An analysis of ovarian tumor tissues collected from patients enrolled in our clinical cohort revealed that dual positivity for BMI-1 and VEGF-A was associated with poor progression-free survival. Overall, DHA targets the miR-200b\u2013BMI-1\/VEGF-A axis to suppress cancer stemness and metastatic potential, highlighting its therapeutic promise in overcoming the limitations of standard chemotherapy for ovarian cancer. The clinical trial number for this study is not applicable.<\/jats:p>","DOI":"10.1038\/s12276-025-01582-2","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T01:06:28Z","timestamp":1764896788000},"page":"2782-2797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b\u2013BMI-1\/VEGF-A axis in ovarian cancer"],"prefix":"10.1038","volume":"57","author":[{"given":"Jin Gu","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsik","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihea","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasol","family":"Yeom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7367-2586","authenticated-orcid":false,"given":"Woochul","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Yeon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyong","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Soo","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Un","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8082-0214","authenticated-orcid":false,"given":"Jong Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-6230","authenticated-orcid":false,"given":"Keun Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-5564","authenticated-orcid":false,"given":"Kyung Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Su","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-3368","authenticated-orcid":false,"given":"Jongmin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s12276-024-01184-4","volume":"56","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. Exp. Mol. Med. 56, 600\u2013615 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/1878-0261.13726","volume":"19","author":"K Bischof","year":"2025","unstructured":"Bischof, K. et al. Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways. Mol. Oncol. 19, 81\u201398 (2025).","journal-title":"Mol. Oncol."},{"key":"1582_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102127","volume":"35","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Global characterization of RNA editing in genetic regulation of multiple ovarian cancer subtypes. Mol. Ther. Nucleic Acids 35, 102127 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5483\/BMBRep.2024-0167","volume":"58","author":"HY Sung","year":"2025","unstructured":"Sung, H. Y. et al. MBNL2 enhances cisplatin resistance by regulating apoptosis in ovarian cancer cells. BMB Rep. 58, 224\u2013231 (2025).","journal-title":"BMB Rep."},{"key":"1582_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.freeradbiomed.2024.02.004","volume":"214","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. \u03b2-sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN\/PI3K\/AKT signaling pathway in ovarian cancer. Free Radic. Biol. Med 214, 137\u2013157 (2024).","journal-title":"Free Radic. Biol. Med"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/19768354.2025.2520852","volume":"29","author":"SJ Lee","year":"2025","unstructured":"Lee, S. J., Kim, K. K. & Lee, J. Y. Bavachin enhances paclitaxel sensitivity in ovarian cancer cells through modulation of mitochondrial function and ER stress. Anim. Cells Syst. 29, 28\u201339 (2025).","journal-title":"Anim. Cells Syst."},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.18632\/genesandcancer.142","volume":"8","author":"C Mehner","year":"2017","unstructured":"Mehner, C. et al. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes Cancer 8, 589\u2013599 (2017).","journal-title":"Genes Cancer"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.3390\/ijms221910689","volume":"22","author":"F Esposito","year":"2021","unstructured":"Esposito, F., Giuffrida, R., Raciti, G., Puglisi, C. & Forte, S. Wee1 kinase: a potential target to overcome tumor resistance to therapy. Int. J. Mol. Sci. 22, 10689 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1582_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5483\/BMBRep.2022-0202","volume":"56","author":"HY Sung","year":"2023","unstructured":"Sung, H. Y. et al. Identification of a novel PARP4 gene promoter CpG locus associated with cisplatin chemoresistance. BMB Rep. 56, 347\u2013352 (2023).","journal-title":"BMB Rep."},{"key":"1582_CR10","first-page":"CD007929","volume":"2015","author":"AJ Wiggans","year":"2015","unstructured":"Wiggans, A. J., Cass, G. K., Bryant, A., Lawrie, T. A. & Morrison, J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst. Rev. 2015, CD007929 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1582_CR11","doi-asserted-by":"publisher","first-page":"e0279286","DOI":"10.1371\/journal.pone.0279286","volume":"17","author":"H Ding","year":"2022","unstructured":"Ding, H. et al. Cost-effectiveness of PARP inhibitors in malignancies: a systematic review. PLoS ONE 17, e0279286 (2022).","journal-title":"PLoS ONE"},{"key":"1582_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.freeradbiomed.2022.03.001","volume":"182","author":"YJ Lee","year":"2022","unstructured":"Lee, Y. J. et al. Plasma-activated medium inhibits cancer stem cell-like properties and exhibits a synergistic effect in combination with cisplatin in ovarian cancer. Free Radic. Biol. Med. 182, 276\u2013288 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s12276-023-01014-z","volume":"55","author":"ML Jin","year":"2023","unstructured":"Jin, M. L. & Jeong, K. W. Histone modifications in drug-resistant cancers: from a cancer stem cell and immune evasion perspective. Exp. Mol. Med. 55, 1333\u20131347 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1582_CR14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/1878-0261.13815","volume":"19","author":"HE Lien","year":"2025","unstructured":"Lien, H. E. et al. Multiplex single-cell profiling of putative cancer stem cell markers ALDH1, SOX9, SOX2, CD44, CD133 and CD15 in endometrial cancer. Mol. Oncol. 19, 1651\u20131667 (2025).","journal-title":"Mol. Oncol."},{"key":"1582_CR15","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1158\/0008-5472.CAN-09-4229","volume":"70","author":"Z Jagani","year":"2010","unstructured":"Jagani, Z. et al. The polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res. 70, 5528\u20135538 (2010).","journal-title":"Cancer Res."},{"key":"1582_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0406-z","volume":"11","author":"Q Zhao","year":"2018","unstructured":"Zhao, Q. et al. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR\/Cas9 system and RNA sequencing. J. Ovarian Res. 11, 31 (2018).","journal-title":"J. Ovarian Res."},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"8231","DOI":"10.3390\/ijms23158231","volume":"23","author":"J Xu","year":"2022","unstructured":"Xu, J., Li, L., Shi, P., Cui, H. & Yang, L. The crucial roles of Bmi-1 in cancer: implications in pathogenesis, metastasis, drug resistance, and targeted therapies. Int. J. Mol. Sci. 23, 8231 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1582_CR18","doi-asserted-by":"crossref","unstructured":"Safa, A. R. Resistance to drugs and cell death in cancer stem cells (CSCs). J. Transl. Sci. 6, 341 (2020).","DOI":"10.15761\/JTS.1000341"},{"key":"1582_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/stem.1035","volume":"30","author":"HR Siddique","year":"2012","unstructured":"Siddique, H. R. & Saleem, M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 30, 372\u2013378 (2012).","journal-title":"Stem Cells"},{"key":"1582_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-133","volume":"10","author":"GF Yang","year":"2010","unstructured":"Yang, G. F. et al. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer 10, 133 (2010).","journal-title":"BMC Cancer"},{"key":"1582_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/19768354.2024.2402024","volume":"28","author":"B Kim","year":"2024","unstructured":"Kim, B., Park, Y. Y. & Lee, J. H. CXCL10 promotes melanoma angiogenesis and tumor growth. Anim. Cells Syst. 28, 453\u2013465 (2024).","journal-title":"Anim. Cells Syst."},{"key":"1582_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102363","volume":"35","author":"S Kim","year":"2024","unstructured":"Kim, S., Park, S., Kim, Y. J., Hyun, J. & Choi, J. miRNA-199b-5p suppresses of oral squamous cell carcinoma by targeting apical-basolateral polarity via Scribble\/Lgl. Mol. Ther. Nucleic Acids 35, 102363 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1582_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.freeradbiomed.2025.02.007","volume":"230","author":"SK Tiwari","year":"2025","unstructured":"Tiwari, S. K. et al. Hypoxia induced mitophagy generates reversible metabolic and redox heterogeneity with transient cell death switch driving tumorigenesis. Free Radic. Biol. Med. 230, 190\u2013208 (2025).","journal-title":"Free Radic. Biol. Med."},{"key":"1582_CR24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.omtn.2023.05.021","volume":"32","author":"F Bestepe","year":"2023","unstructured":"Bestepe, F. et al. Deficiency of miR-409-3p improves myocardial neovascularization and function through modulation of DNAJB9\/p38 MAPK signaling. Mol. Ther. Nucleic Acids 32, 995\u20131009 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1582_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/19768354.2016.1220976","volume":"20","author":"M Zand-vakili","year":"2016","unstructured":"Zand-vakili, M. et al. Histological evaluation of the effect of VEGF on auto-transplanted mouse ovaries. Anim. Cells Syst. 20, 260\u2013266 (2016).","journal-title":"Anim. Cells Syst."},{"key":"1582_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2024.100128","volume":"47","author":"D Kim","year":"2024","unstructured":"Kim, D., Yoon, M. S., Lee, J., Park, S. Y. & Han, J. S. Effects of phospholipase D1-inhibitory peptide on the growth and metastasis of gastric cancer cells. Mol. Cells 47, 100128 (2024).","journal-title":"Mol. Cells"},{"key":"1582_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/cancers13061422","volume":"13","author":"FT Zahra","year":"2021","unstructured":"Zahra, F. T., Sajib, M. S. & Mikelis, C. M. Role of bFGF in acquired resistance upon anti-VEGF therapy in cancer. Cancers 13, 1422 (2021).","journal-title":"Cancers"},{"key":"1582_CR28","first-page":"144","volume":"12","author":"V Wieser","year":"2019","unstructured":"Wieser, V. & Marth, C. Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer. Memo Mag. Eur. Med. Oncol. 12, 144\u2013148 (2019).","journal-title":"Memo Mag. Eur. Med. Oncol."},{"key":"1582_CR29","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.2147\/CMAR.S164675","volume":"10","author":"H Ge","year":"2018","unstructured":"Ge, H. & Luo, H. Overview of advances in vasculogenic mimicry\u2014a potential target for tumor therapy. Cancer Manag. Res. 10, 2429\u20132437 (2018).","journal-title":"Cancer Manag. Res."},{"key":"1582_CR30","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.7150\/jca.34171","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Zhang, J., Zhou, H., Fan, G. & Li, Q. Molecular mechanisms and anticancer therapeutic strategies in vasculogenic mimicry. J. Cancer 10, 6327\u20136340 (2019).","journal-title":"J. Cancer"},{"key":"1582_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4161\/cbt.316","volume":"1","author":"AK Sood","year":"2002","unstructured":"Sood, A. K. et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol. Ther. 1, 661\u2013664 (2002).","journal-title":"Cancer Biol. Ther."},{"key":"1582_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5483\/BMBRep.2019.52.3.308","volume":"52","author":"Y Park","year":"2019","unstructured":"Park, Y. & Kim, J. Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells. BMB Rep. 52, 214\u2013219 (2019).","journal-title":"BMB Rep."},{"key":"1582_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5483\/BMBRep.2018.51.7.112","volume":"51","author":"YC Chae","year":"2018","unstructured":"Chae, Y. C. & Kim, J. H. Cancer stem cell metabolism: target for cancer therapy. BMB Rep. 51, 319\u2013326 (2018).","journal-title":"BMB Rep."},{"key":"1582_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-207","volume":"13","author":"D Zhang","year":"2014","unstructured":"Zhang, D. et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol. Cancer 13, 207 (2014).","journal-title":"Mol. Cancer"},{"key":"1582_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/labinvest.2010.52","volume":"90","author":"SA Adham","year":"2010","unstructured":"Adham, S. A., Sher, I. & Coomber, B. L. Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells. Lab. Invest. 90, 709\u2013723 (2010).","journal-title":"Lab. Invest."},{"key":"1582_CR36","doi-asserted-by":"publisher","first-page":"e0137331","DOI":"10.1371\/journal.pone.0137331","volume":"10","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Mechanisms of dihydroartemisinin and dihydroartemisinin\/holotransferrin cytotoxicity in T-cell lymphoma cells. PLoS ONE 10, e0137331 (2015).","journal-title":"PLoS ONE"},{"key":"1582_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/ddr.20344","volume":"71","author":"RJ Maude","year":"2010","unstructured":"Maude, R. J., Woodrow, C. J. & White, L. J. Artemisinin antimalarials: preserving the magic bullet. Drug Dev. Res. 71, 12\u201319 (2010).","journal-title":"Drug Dev. Res."},{"key":"1582_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-6-15","volume":"6","author":"S Dellicour","year":"2007","unstructured":"Dellicour, S., Hall, S., Chandramohan, D. & Greenwood, B. The safety of artemisinins during pregnancy: a pressing question. Malar. J. 6, 15 (2007).","journal-title":"Malar. J."},{"key":"1582_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/diagnostics9030120","volume":"9","author":"P Tudrej","year":"2019","unstructured":"Tudrej, P., Kujawa, K. A., Cortez, A. J. & Lisowska, K. M. Characteristics of in vivo model systems for ovarian cancer studies. Diagnostics 9, 120 (2019).","journal-title":"Diagnostics"},{"key":"1582_CR40","doi-asserted-by":"publisher","first-page":"R339","DOI":"10.1530\/ERC-14-0550","volume":"22","author":"H Gharwan","year":"2015","unstructured":"Gharwan, H., Bunch, K. P. & Annunziata, C. M. The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr. Relat. Cancer 22, R339\u2013R363 (2015).","journal-title":"Endocr. Relat. Cancer"},{"key":"1582_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cells9010008","volume":"9","author":"X Jiao","year":"2019","unstructured":"Jiao, X. et al. microRNA: the impact on cancer stemness and therapeutic resistance. Cells 9, 8 (2019).","journal-title":"Cells"},{"key":"1582_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01920-0","volume":"21","author":"Y Tang","year":"2021","unstructured":"Tang, Y. et al. MicroRNAs and angiogenesis: a new era for the management of colorectal cancer. Cancer Cell Int 21, 221 (2021).","journal-title":"Cancer Cell Int"},{"key":"1582_CR43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/onc.2011.263","volume":"31","author":"L Sun","year":"2012","unstructured":"Sun, L. et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31, 432\u2013445 (2012).","journal-title":"Oncogene"},{"key":"1582_CR44","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1161\/ATVBAHA.111.236521","volume":"31","author":"A Chamorro-Jorganes","year":"2011","unstructured":"Chamorro-Jorganes, A. et al. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb. Vasc. Biol. 31, 2595\u20132606 (2011).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"1582_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0859-x","volume":"31","author":"Q Liu","year":"2014","unstructured":"Liu, Q. et al. miR-200b as a prognostic factor targets multiple members of RAB family in glioma. Med. Oncol. 31, 859 (2014).","journal-title":"Med. Oncol."},{"key":"1582_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3389\/fonc.2020.00643","volume":"10","author":"HF Jin","year":"2020","unstructured":"Jin, H. F., Wang, J. F., Song, T. T., Zhang, J. & Wang, L. MiR-200b inhibits tumor growth and chemoresistance via targeting p70S6K1 in lung cancer. Front. Oncol. 10, 643 (2020).","journal-title":"Front. Oncol."},{"key":"1582_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.biopha.2012.06.002","volume":"66","author":"B Feng","year":"2012","unstructured":"Feng, B., Wang, R. & Chen, L. B. Review of miR-200b and cancer chemosensitivity. Biomed. Pharmacother. 66, 397\u2013402 (2012).","journal-title":"Biomed. Pharmacother."},{"key":"1582_CR48","doi-asserted-by":"crossref","unstructured":"Cho, J. G. et al. Loss of primary cilia promotes EphA2-mediated endothelial-to-mesenchymal transition in the ovarian tumor microenvironment. Mol. Oncol. 19, 2951\u20132966 (2025).","DOI":"10.1002\/1878-0261.70057"},{"key":"1582_CR49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053\u20131064 (2010).","journal-title":"Am. J. Pathol."},{"key":"1582_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10585-004-5768-5","volume":"21","author":"KM Burleson","year":"2004","unstructured":"Burleson, K. M., Hansen, L. K. & Skubitz, A. P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 21, 685\u2013697 (2004).","journal-title":"Clin. Exp. Metastasis"},{"key":"1582_CR51","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/medicina59030544","volume":"59","author":"A Havasi","year":"2023","unstructured":"Havasi, A., Cainap, S. S., Havasi, A. T. & Cainap, C. Ovarian cancer-insights into platinum resistance and overcoming it. Medicina 59, 544 (2023).","journal-title":"Medicina"},{"key":"1582_CR52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fonc.2020.00413","volume":"10","author":"E Lizarraga-Verdugo","year":"2020","unstructured":"Lizarraga-Verdugo, E. et al. Cancer stem cells and its role in angiogenesis and vasculogenic mimicry in gastrointestinal cancers. Front. Oncol. 10, 413 (2020).","journal-title":"Front. Oncol."},{"key":"1582_CR53","doi-asserted-by":"publisher","first-page":"15279","DOI":"10.1021\/acs.jmedchem.0c01336","volume":"63","author":"PS Kharkar","year":"2020","unstructured":"Kharkar, P. S. Cancer stem cell (CSC) inhibitors in oncology\u2014a promise for a better therapeutic outcome: state of the art and future perspectives. J. Med. Chem. 63, 15279\u201315307 (2020).","journal-title":"J. Med. Chem."},{"key":"1582_CR54","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s00432-021-03701-8","volume":"147","author":"R Zheng","year":"2021","unstructured":"Zheng, R., Li, F., Li, F. & Gong, A. Targeting tumor vascularization: promising strategies for vascular normalization. J. Cancer Res. Clin. Oncol. 147, 2489\u20132505 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1582_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722331","volume":"11","author":"R Yu","year":"2021","unstructured":"Yu, R., Jin, G. & Fujimoto, M. Dihydroartemisinin: a potential drug for the treatment of malignancies and inflammatory diseases. Front Oncol. 11, 722331 (2021).","journal-title":"Front Oncol."},{"key":"1582_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fnagi.2020.00047","volume":"12","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. Dihydroartemisinin ameliorates learning and memory in Alzheimer\u2019s disease through promoting autophagosome\u2013lysosome fusion and autolysosomal degradation for abeta clearance. Front. Aging Neurosci. 12, 47 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"1582_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105737","volume":"122","author":"T Li","year":"2022","unstructured":"Li, T. et al. Dihydroartemisinin alleviates steatosis and inflammation in nonalcoholic steatohepatitis by decreasing endoplasmic reticulum stress and oxidative stress. Bioorg. Chem. 122, 105737 (2022).","journal-title":"Bioorg. Chem."},{"key":"1582_CR58","doi-asserted-by":"publisher","DOI":"10.1590\/acb385023","volume":"38","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. Dihydroartemisinin ameliorates the liver steatosis in metabolic associated fatty liver disease mice by attenuating the inflammation and oxidative stress and promoting autophagy. Acta Cir. Bras. 38, e385023 (2023).","journal-title":"Acta Cir. Bras."},{"key":"1582_CR59","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1038\/s41401-022-00898-3","volume":"43","author":"W Zhou","year":"2022","unstructured":"Zhou, W. et al. Dihydroartemisinin suppresses renal fibrosis in mice by inhibiting DNA-methyltransferase 1 and increasing Klotho. Acta Pharm. Sin. 43, 2609\u20132623 (2022).","journal-title":"Acta Pharm. Sin."},{"key":"1582_CR60","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.18632\/aging.203874","volume":"14","author":"X You","year":"2022","unstructured":"You, X. et al. Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2\/STAT3 signaling. Aging 14, 1110\u20131127 (2022).","journal-title":"Aging"},{"key":"1582_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.7150\/ijbs.50364","volume":"17","author":"X Dai","year":"2021","unstructured":"Dai, X. et al. Dihydroartemisinin: a potential natural anticancer drug. Int. J. Biol. Sci. 17, 603\u2013622 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"1582_CR62","doi-asserted-by":"publisher","first-page":"e17918","DOI":"10.1371\/journal.pone.0017918","volume":"6","author":"E Wang","year":"2011","unstructured":"Wang, E. et al. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS ONE 6, e17918 (2011).","journal-title":"PLoS ONE"},{"key":"1582_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2023.1080255","volume":"4","author":"AE Herzog","year":"2023","unstructured":"Herzog, A. E., Somayaji, R. & Nor, J. E. Bmi-1: a master regulator of head and neck cancer stemness. Front. Oral Health 4, 1080255 (2023).","journal-title":"Front. Oral Health"},{"key":"1582_CR64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.canlet.2015.05.010","volume":"380","author":"YF Ping","year":"2016","unstructured":"Ping, Y. F., Zhang, X. & Bian, X. W. Cancer stem cells and their vascular niche: do they benefit from each other? Cancer Lett. 380, 561\u2013567 (2016).","journal-title":"Cancer Lett."},{"key":"1582_CR65","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41401-018-0050-6","volume":"40","author":"XT Qi","year":"2019","unstructured":"Qi, X. T. et al. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharm. Sin. 40, 546\u2013555 (2019).","journal-title":"Acta Pharm. Sin."},{"key":"1582_CR66","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","volume":"26","author":"CE Eyler","year":"2008","unstructured":"Eyler, C. E. & Rich, J. N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839\u20132845 (2008).","journal-title":"J. Clin. Oncol."},{"key":"1582_CR67","doi-asserted-by":"publisher","first-page":"e55527","DOI":"10.1371\/journal.pone.0055527","volume":"8","author":"L Jiang","year":"2013","unstructured":"Jiang, L. et al. Bmi-1 promotes glioma angiogenesis by activating NF-\u03baB signaling. PLoS ONE 8, e55527 (2013).","journal-title":"PLoS ONE"},{"key":"1582_CR68","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1158\/2159-8290.CD-12-0085","volume":"2","author":"HL Goel","year":"2012","unstructured":"Goel, H. L. et al. VEGF\/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov. 2, 906\u2013921 (2012).","journal-title":"Cancer Discov."},{"key":"1582_CR69","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5483\/BMBRep.2020.53.6.060","volume":"53","author":"D Lim","year":"2020","unstructured":"Lim, D. et al. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer. BMB Rep. 53, 291\u2013298 (2020).","journal-title":"BMB Rep."},{"key":"1582_CR70","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4161\/cbt.7.5.5765","volume":"7","author":"JY Wang","year":"2008","unstructured":"Wang, J. Y. et al. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol. Ther. 7, 758\u2013766 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"1582_CR71","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.omtn.2022.08.028","volume":"29","author":"JG Cho","year":"2022","unstructured":"Cho, J. G. et al. MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. Mol. Ther. Nucleic Acids 29, 803\u2013822 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1582_CR72","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.canlet.2016.11.017","volume":"386","author":"JY Jeong","year":"2017","unstructured":"Jeong, J. Y. et al. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 386, 168\u2013178 (2017).","journal-title":"Cancer Lett."},{"key":"1582_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0766-4","volume":"17","author":"Y Wang","year":"2018","unstructured":"Wang, Y., Wang, L., Chen, C. & Chu, X. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications. Mol. Cancer 17, 22 (2018).","journal-title":"Mol. Cancer"},{"key":"1582_CR74","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1210\/clinem\/dgaa538","volume":"105","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. MicroRNA-15b targets VEGF and inhibits angiogenesis in proliferative diabetic retinopathy. J. Clin. Endocrinol. Metab. 105, 3404\u20133415 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1582_CR75","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/jcmm.12432","volume":"19","author":"Y Yao","year":"2015","unstructured":"Yao, Y. et al. MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J. Cell. Mol. Med. 19, 760\u2013769 (2015).","journal-title":"J. Cell. Mol. Med."},{"key":"1582_CR76","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1182\/blood-2004-07-2909","volume":"105","author":"K Podar","year":"2005","unstructured":"Podar, K. & Anderson, K. C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105, 1383\u20131395 (2005).","journal-title":"Blood"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01582-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01582-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01582-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:02:23Z","timestamp":1768323743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01582-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":76,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01582-2","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have provided consent for the publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All study participants provided informed consent via signed forms, and the study design was approved by the Institutional Review Board of Pusan National University Hospital (IRB-2001-010-087). The animal experiments were conducted in accordance with the regulations of Pusan National University Hospital, and all procedures were performed in accordance with the policies of the Institutional Animal Care and Use Committee of Pusan National University of Korea (PNUH-2017-110).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}